Allogene Therapeutics, Inc. (ALLO)

Allogene Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	51.69	75.22	83.16	61.9	173.31
Short-Term Investments	198.52	217.26	365.54	455.42	283.99
Cash & Short-Term Investments	250.21	292.48	448.7	517.32	457.3
Cash Growth	-14.45%	-34.82%	-13.26%	13.12%	-44.76%
Other Current Assets	7.54	10.91	10.42	11.5	14.02
Total Current Assets	257.75	303.39	459.12	528.82	471.32
Net Property, Plant & Equipment	112.73	131.26	163.18	196.43	181.02
Long-Term Investments	8.04	80.67	3.65	76.47	382.38
Other Long-Term Assets	37.39	33.39	16.9	19.86	16.11
Total Assets	415.91	548.71	642.84	821.58	1,051
Accounts Payable	4.27	5.39	5.9	13.89	10.26
Accrued Expenses	28.24	30.13	31.18	39.74	37.5
Unearned Revenue	-	-	-	0.1	0.16
Total Current Liabilities	32.51	35.52	37.08	53.73	47.91
Long-Term Leases	75.05	83.25	88.35	95.12	69.93
Other Long-Term Liabilities	15.8	7.76	5.18	5.85	7.79
Total Long-Term Liabilities	90.85	91.01	93.53	100.97	77.72
Total Liabilities	123.36	126.53	130.6	154.7	125.63
Common Stock	0.23	0.21	0.17	0	0.14
Additional Paid-in Capital	2,303	2,242	2,075	1,912	1,822
Accumulated Other Comprehensive Income	0.27	-0.09	-0.96	-9.93	-2.57
Retained Earnings	-2,011	-1,820	-1,562	-1,235	-894.55
Shareholders' Equity	292.54	422.18	512.23	666.88	925.2
Total Liabilities & Equity	415.91	548.71	642.84	821.58	1,051
Total Debt	75.05	83.25	88.35	95.12	69.93
Net Cash (Debt)	175.17	209.23	360.35	422.2	387.37
Net Cash Growth	-16.28%	-41.94%	-14.65%	8.99%	-50.15%
Net Cash Per Share	0.79	1.07	2.30	2.95	2.85
Book Value	292.54	422.18	512.23	666.88	925.2
Book Value Per Share	1.33	2.17	3.26	4.66	6.81
Tangible Book Value	292.54	422.18	512.23	666.88	925.2
Tangible Book Value Per Share	1.33	2.17	3.26	4.66	6.81

Updated Mar 12, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q